All G LFX Precision-Fermented Apo-Lactoferrin

All G is an Australian biotechnology company founded in Sydney in 2021 that develops high-value human and bovine milk proteins through precision fermentation. Lactoferrin is scarce in milk and costly to extract, which limits its use in infant formula, supplements and personal care.

Its platform combines strain engineering in a biofoundry, yeast fermentation in stainless-steel tanks, multi-step purification and batch analytics such as HPLC and LC-MS. The first product, LFX, is a bovine apo-lactoferrin with low iron saturation and over 95% purity, produced without animal inputs and described as bio-equivalent to native lactoferrin with higher antioxidant activity. All G supplies ingredients, technical support, regulatory documentation and claims dossiers to infant formula, supplement and personal care companies in Asia-Pacific, China, Europe and the U.S.

• LFX apo-lactoferrin: precision-fermented bovine lactoferrin with low iron saturation.
• Biofoundry strain engineering: food-grade yeast strains optimised to express the target protein.
• Controlled fermentation: temperature, pH, oxygen and nutrient control from pilot to large batches.
• Purification and analytics: removal of host-cell proteins and nucleic acids, with HPLC and LC-MS testing.
• Application range: early life nutrition, women's health, sports nutrition, healthy ageing and personal care.
• Customer support: ingredient supply plus regulatory documents, clinical data and claims dossiers.

• Vietnamese infant and growing-up milk producers fortifying formulas with lactoferrin.
• Supplement companies developing iron-support products for pregnant women and women of reproductive age.
• Cosmetic and oral care brands adding lactoferrin to acne or gum health products.

• High purity and consistency: over 95% purity with batch-level analytical characterisation.
• Stronger functionality: low iron saturation maximises iron-binding capacity, with higher antioxidant activity than native bovine lactoferrin in the company's testing.
• Market access: China CSAR approval in 2024 and an FDA GRAS 'no questions' letter in 2026.
• Supply security: fermentation-based production avoids dependence on limited milk and colostrum supply.

China is the largest lactoferrin market and infant formula makers across Asia are adding bioactive proteins to bring formulas closer to breast milk. Iron deficiency among women and demand for immunity products are widening use in supplements, while precision fermentation offers a scalable alternative to milk-derived lactoferrin.

Founded in Sydney in 2021; headquartered in Zetland/Waterloo, Sydney, Australia. Total funding of about AUD 45 million by 2022 and a further AUD 10 million in 2025. Pilot partnership with Doehler in Germany; joint venture with Armor Proteines (Savencia Group) to manufacture and commercialise lactoferrin. China CSAR approval in 2024, FDA GRAS 'no questions' in 2026.